.jpg "Sander Palit, PhD photo")
Product Developer Oncogenetics
MRC Holland
Sander Palit, PhD is working as a Product Developer at the Oncogenetics department of MRC Holland, a biotechnology company specialized in the design of assays for the detection of DNA copy number alterations (CNAs), mutations and methylation patterns associated with disease.
Sander’s work focuses on developing new and updating existing SALSA® MLPA® and SALSA® digitalMLPA™ probemixes for the detection of CNAs and selected mutations associated with cancer. The most recent probemix Sander has worked on, which he will also present at the AMP meeting with a poster, is the SALSA® MLPA® probemix P496 KMT2A.
Prior to his graduate studies, Sander obtained his Master’s degree in Medical Biology at the Radboud University in Nijmegen, specializing in molecular biology in cancer. There, he focussed on transcription factors and epigenetic regulators, and how their aberrant function plays a role in tumorigenesis and therapy response. Sander then obtained his PhD at the Netherlands Cancer Institute (NKI) in Amsterdam, where he applied CRISPR-Cas9 technology in functional genetic screens for the unbiased identification of genes that have a central role in prostate cancer biology and therapy response. Through this approach he provided novel insight into molecular mechanisms underlying aberrant cell signalling and drug resistance in prostate cancer.